DNA methylation of<i> ANKRD23</i> as a novel biomarker for early diagnosis of ovarian cancer


Alizada A., Erdogan Ö., Erciyas S., Demirbas B. C., Pasin O., Dinc A., ...Daha Fazla

AFRICAN JOURNAL OF REPRODUCTIVE HEALTH, cilt.30, sa.15, ss.16-25, 2026 (SSCI, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 15
  • Basım Tarihi: 2026
  • Doi Numarası: 10.29063/ajrh2026/v30i15.2
  • Dergi Adı: AFRICAN JOURNAL OF REPRODUCTIVE HEALTH
  • Derginin Tarandığı İndeksler: Social Sciences Citation Index (SSCI), Scopus, CAB Abstracts, CINAHL, Index Islamicus, MEDLINE, Middle East & Africa Database (ProQuest), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
  • Sayfa Sayıları: ss.16-25
  • İstanbul Üniversitesi Adresli: Evet

Özet

Ovarian cancer (OC) is a leading cause of gynecologic cancer-related mortality and is frequently diagnosed at advanced stages due to the absence of effective early detection tools. Epigenetic alterations, particularly DNA methylation, play a critical role in tumorigenesis and represent promising non-invasive biomarkers. This study investigated the methylation status of the ANKRD23 gene in OC and evaluated its diagnostic potential using peripheral blood samples. A total of 385 serous OC patients, 50 individuals with benign ovarian conditions, and 99 healthy controls were included. DNA methylation was assessed using methylation-sensitive restriction enzymes followed by real-time PCR. ANKRD23 methylation was significantly associated with clinical stage (p = 0.029), histological grade (p = 0.009), and ethnicity (p = 0.024). Moreover, methylation levels differed significantly among OC patients, benign cases, and healthy controls (p = 0.026). These findings support blood-basedANKRD23 methylation as a promising biomarker for non-invasive ovarian cancer diagnosis and risk stratification. (Afr JReprod Health 2026; 30 [15] 16-25).